Quercetin 4 studies - early treatment 79% and pre-exposure prophylaxis 92%

[admin]

While quercetin is new to the trials section, many of us have been taking quercetin, zinc and vitamin D and C (helps the quercetin transport the zinc into the cell where it inhibits viral replication) since spring of 2020 on the advice of Dr. Vladimir Zelenko.

Quercetin 4 studies
https://c19quercetin.com/

Early treatment 86%
https://c19quercetin.com/dipierro.html
risk of death, 85.7% lower, RR 0.14, p = 0.25, treatment 0 of 76 (0.0%), control 3 of 76 (3.9%), continuity correction due to zero event (with reciprocal of the contrasting arm).
risk of ICU admission, 94.1% lower, RR 0.06, p = 0.006, treatment 0 of 76 (0.0%), control 8 of 76 (10.5%), continuity correction due to zero event (with reciprocal of the contrasting arm).
risk of hospitalization, 68.2% lower, RR 0.32, p = 0.003, treatment 7 of 76 (9.2%), control 22 of 76 (28.9%).

Early treatment 67%
https://c19quercetin.com/dipierro2.html
risk of death, 66.7% lower, RR 0.33, p = 1.00, treatment 0 of 21 (0.0%), control 1 of 21 (4.8%), continuity correction due to zero event (with reciprocal of the contrasting arm).
risk of ICU admission, 66.7% lower, RR 0.33, p = 1.00, treatment 0 of 21 (0.0%), control 1 of 21 (4.8%), continuity correction due to zero event (with reciprocal of the contrasting arm).
risk of hospitalization, 66.7% lower, RR 0.33, p = 1.00, treatment 0 of 21 (0.0%), control 1 of 21 (4.8%), continuity correction due to zero event (with reciprocal of the contrasting arm).
risk of no virological cure, 73.7% lower, RR 0.26, p < 0.001, treatment 5 of 21 (23.8%), control 19 of 21 (90.5%), day 7.
risk of no virological cure, 88.9% lower, RR 0.11, p = 0.11, treatment 0 of 21 (0.0%), control 4 of 21 (19.0%), continuity correction due to zero event (with reciprocal of the contrasting arm), day 14.

Pre-exposure prophylaxis 92%
https://c19quercetin.com/onal.html
risk of COVID-19 case, 91.7% lower, RR 0.08, p = 0.03, treatment 1 of 71 (1.4%), control 9 of 42 (21.4%), adjusted per study.

Late treatment 29.3% higher
RCT 447 moderate-to-severe hospitalized patients in Turkey, 52 treated with quercetin, bromelain, and vitamin C, showing no statistically significant difference in clinical outcomes.
https://c19quercetin.com/onal.html
risk of death, 29.3% higher, RR 1.29, p = 0.57, treatment 1 of 49 (2.0%), control 6 of 380 (1.6%). (That's 1 in every 63 for control, which if the treated group had been 63, may well have wound up the same.)
risk of ICU admission, 94.0% lower, RR 0.06, p = 0.39, treatment 0 of 49 (0.0%), control 14 of 380 (3.7%), continuity correction due to zero event (with reciprocal of the contrasting arm).
risk of no hospital discharge, 77.8% lower, RR 0.22, p = 0.10, treatment 1 of 49 (2.0%), control 35 of 380 (9.2%).